Keeps Clinical Gaps and Limitations: What the Subscription Model Misses

What Keeps Actually Prescribes

Keeps offers two FDA-approved medications: oral finasteride 1 mg daily and topical minoxidil 5% solution or foam. That is the entire clinical menu. Finasteride blocks type II 5-alpha reductase, reducing scalp dihydrotestosterone (DHT) by roughly 70% at the 1 mg dose [1]. Minoxidil acts as a potassium channel opener that prolongs anagen phase and increases follicular blood flow [2].

Both drugs have strong evidence behind them. A 5-year extension of the original Merck trial showed finasteride maintained or improved hair counts in 65% of men at year five versus 0% in the placebo group [3]. Topical minoxidil 5% produces visible regrowth in approximately 40% of users at 48 weeks, per a randomized trial of 393 men published in the Journal of the American Academy of Dermatology [4]. These are real drugs with real data. The question is not whether they work. The question is whether two medications are enough for every patient walking through a digital door.

The American Academy of Dermatology (AAD) guidelines list finasteride and minoxidil as first-line, but they also include low-dose oral minoxidil, platelet-rich plasma (PRP), and combination approaches as part of a broader toolkit [5]. Keeps does not offer any of these alternatives.

The Dutasteride Gap

Dutasteride 0.5 mg inhibits both type I and type II 5-alpha reductase, reducing serum DHT by more than 90%, compared to the roughly 70% reduction with finasteride [6]. A phase III randomized trial (N=917) published in the Journal of the American Academy of Dermatology found that dutasteride 0.5 mg produced significantly greater hair count increases than finasteride 1 mg at 24 weeks: 109.6 hairs versus 75.6 hairs in a 2.54 cm² target area [7].

This matters for a specific population. Men who have taken finasteride for 12 months or longer without adequate response represent a well-recognized clinical scenario. Dr. Jerry Shapiro, a professor of dermatology at NYU Langone, has noted that "dutasteride is a reasonable next step for men who have had an incomplete response to finasteride, given its broader enzyme inhibition profile" [8]. Keeps has no pathway to offer this escalation. A patient who plateaus on finasteride through Keeps must find a new provider to access dutasteride.

Dutasteride is FDA-approved for benign prostatic hyperplasia, not alopecia, which makes it an off-label prescription for hair loss. Off-label use is legal and common in dermatology, but it requires clinical judgment. The subscription model's narrow formulary sidesteps this judgment call entirely.

No Bloodwork, No Hormonal Baseline

Keeps does not order or require any laboratory testing. No complete blood count. No ferritin. No thyroid panel. No testosterone or DHT levels. This is a significant omission for a platform treating a hormone-mediated condition.

Iron deficiency (ferritin <30 ng/mL) is a recognized contributor to diffuse hair loss, particularly telogen effluvium, which can mimic or coexist with androgenetic alopecia [9]. Thyroid dysfunction affects roughly 5% of the U.S. adult population, and both hypothyroidism and hyperthyroidism cause hair changes that will not respond to finasteride [10]. Without screening, a patient with low ferritin or subclinical hypothyroidism could spend months on a subscription treating the wrong diagnosis.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends measuring total testosterone in men presenting with symptoms potentially linked to androgen imbalance [11]. Hair loss in younger men (under 25) can occasionally signal hormonal conditions that warrant evaluation beyond pattern recognition from uploaded photos. Keeps' intake process relies on a questionnaire and asynchronous photo review. No provider on the platform examines the scalp directly or palpates for scarring, inflammation, or signs of other alopecias.

Dr. Antonella Tosti, a professor of dermatology at the University of Miami Miller School of Medicine, has stated: "A correct diagnosis is the most important step in managing hair loss. Without dermoscopy and sometimes biopsy, you risk treating the wrong condition entirely" [12].

The Oral Minoxidil Question

Low-dose oral minoxidil (typically 1.25 to 5 mg daily) has become one of the most discussed developments in hair loss treatment over the past five years. A systematic review and meta-analysis published in the Journal of the American Academy of Dermatology in 2022, covering 17 studies and 634 patients, found that oral minoxidil at doses of 0.25 to 5 mg daily produced clinically meaningful improvement in both androgenetic alopecia and other forms of hair loss, with a favorable side-effect profile at lower doses [13].

Keeps does not prescribe oral minoxidil. This is a meaningful gap for two patient groups: men who find topical application inconvenient or who develop contact dermatitis from the propylene glycol vehicle, and men who want additive benefit beyond what topical application alone provides. Topical minoxidil absorption varies widely between individuals, with some absorbing as little as 1% of the applied dose [2]. Oral dosing bypasses this variability entirely.

The AAD has acknowledged low-dose oral minoxidil in its updated guidance, though it remains off-label for alopecia [5]. Prescribing it safely requires monitoring blood pressure and watching for dose-dependent side effects including fluid retention, tachycardia, and hypertrichosis. This level of monitoring may exceed what a photo-based subscription platform can provide, which likely explains its absence from the Keeps formulary. The limitation is understandable but still leaves patients without access.

Combination Therapy Restrictions

Hair loss treatment in dermatology practice increasingly relies on multi-drug regimens. A finasteride-plus-minoxidil combination is standard, but specialists frequently add compounded topical formulations containing agents like ketoconazole 2%, tretinoin 0.025%, or latanoprost. Some clinics offer dutasteride combined with oral minoxidil for aggressive cases. PRP injections serve as an adjunct in moderate-to-advanced loss [14].

Keeps offers finasteride and minoxidil. Together or separately. That is the extent of combination therapy available. There is no compounding pharmacy relationship, no injectable options, no pathway to multi-agent topical formulations. A 2019 randomized controlled trial in Dermatologic Therapy (N=60) showed that adding PRP to finasteride therapy produced superior hair density improvement at six months compared to finasteride alone [15]. Patients using Keeps who want PRP must coordinate that independently.

The subscription model works well for straightforward Norwood II-III pattern loss in men aged 25 to 45 who respond to first-line therapy. It works less well for anyone outside that narrow window.

The Diagnostic Limitation

Keeps treats androgenetic alopecia. Period. The platform's intake questionnaire and photo submission process are designed to identify male pattern hair loss and exclude obvious contraindications. But hair loss has dozens of causes, and several common ones share visual features with androgenetic alopecia.

Alopecia areata affects approximately 2% of the general population at some point in their lifetime [16]. Telogen effluvium, triggered by stress, illness, medication changes, or nutritional deficiency, produces diffuse thinning that overlaps visually with early pattern loss. Frontal fibrosing alopecia has increased in prevalence over the past two decades and causes a receding hairline that can look nearly identical to male pattern recession in its early stages [17].

A board-certified dermatologist performing an in-person evaluation uses dermoscopy (a handheld magnification tool) to distinguish between these conditions in minutes. Scarring alopecias like frontal fibrosing alopecia or lichen planopilaris require prompt treatment with anti-inflammatory agents, not finasteride. Misdiagnosis delays appropriate care. A scalp biopsy, which Keeps cannot provide, remains the gold standard for ambiguous presentations [12].

Cost and the Subscription Trap

Keeps prices finasteride at roughly $10 per month and minoxidil at approximately $10 to $35 per month depending on formulation, with bundled plans running up to $75 monthly. Generic finasteride 1 mg through a local pharmacy with a GoodRx coupon costs between $3 and $15 for a 30-day supply [18]. Generic topical minoxidil 5% is available over the counter at most pharmacies for $15 to $25 per month.

The subscription model adds convenience. Medication ships to your door. A provider reviews your photos periodically. But the cost premium is not buying expanded clinical access. It is buying logistics. Patients paying $75 per month for a Keeps bundle could see a board-certified dermatologist via telehealth for a comparable or lower total cost once the generic medications are sourced independently, and they would gain access to the full formulary, lab ordering capability, and diagnostic expertise that the subscription model lacks.

Keeps' no-refund-after-shipment policy also creates friction for patients who experience side effects or want to discontinue. Finasteride side effects, while uncommon (occurring in roughly 2 to 4% of users per the original Merck data), include decreased libido, erectile changes, and rarely, persistent symptoms after discontinuation [3]. A patient who fills a three-month supply through Keeps and develops side effects in week two has paid for medication they cannot use and cannot return.

When Keeps Works and When It Does Not

Keeps is a legitimate platform prescribing FDA-approved medications through licensed providers. For a 30-year-old man with early-to-moderate vertex thinning, no complicating medical history, and no prior treatment, finasteride 1 mg plus topical minoxidil 5% is exactly what evidence-based guidelines recommend as a starting point [5]. Keeps delivers this efficiently.

The clinical gaps emerge along predictable lines. Non-responders to finasteride have no escalation path. Men with possible hormonal, thyroid, or nutritional contributors receive no workup. Patients with atypical patterns that could represent scarring or autoimmune alopecia rely on photo review rather than dermoscopy or biopsy. Anyone wanting oral minoxidil, dutasteride, compounded topicals, or PRP must leave the platform entirely.

A 2020 cross-sectional study of direct-to-consumer telehealth dermatology platforms found that diagnostic accuracy for photo-based consultations ranged from 60 to 85%, depending on condition complexity, compared to over 90% for in-person dermatologic evaluation [19]. Pattern hair loss in a textbook presentation falls at the easier end of that spectrum. Anything atypical pushes toward the lower end.

What to Ask Before Subscribing

Three questions separate patients who will do well on Keeps from those who need more. First: has a provider ever examined your scalp in person? If no, the diagnosis is assumed, not confirmed. Second: have you had bloodwork including ferritin, TSH, and free testosterone within the past year? If no, treatable contributors may be missed. Third: have you tried finasteride before, and did it work? If you are a finasteride non-responder, Keeps has nothing else to offer you.

The AAD guidelines recommend that patients with hair loss undergo a thorough medical history, physical examination including hair pull test, and targeted laboratory evaluation before initiating pharmacotherapy [5]. Keeps abbreviates this process by design. For the majority of straightforward cases, the abbreviation may not matter clinically. For the minority where it does, the consequences range from wasted time and money to delayed diagnosis of a progressive scarring alopecia that finasteride cannot treat.

Baseline ferritin should be above 40 ng/mL, TSH between 0.5 and 4.0 mIU/L, and total testosterone assessed if clinical suspicion warrants it, before attributing hair loss to androgenetic alopecia alone [9][10][11].